Skip to main content
APhA DrugInfoLine
Sign in to your APhA membership account
Download a PDF of this month's content | Download a PDF of last month's content |Advanced Search
  • HOME
  • NEURO/PSYCH
    • Neurology
    • Psychiatry
  • HEART/LUNGS
    • Cardiology
    • Focus on Lipids Care
    • Focus on Anticoagulation Care
    • Respiratory
    • Focus on Asthma Care
  • GI/KIDNEYS
    • Gastroenterology
    • Nephrology
  • ENDOCRINE/RHEUM
    • Endocrinology
    • Focus on Diabetes Care
    • Rheumatology
  • ID/CANCERS
    • Infectious Diseases
    • Focus on HIV Care
    • Focus on Immunizations
    • Oncology
  • SELF-CARE
    • Alternative Medicines Corner
    • OTC Medicines Corner
  • PERSONALIZED CARE
    • Drug Interactions Corner
    • Pharmacogenomics Corner
  • Heart/Lungs
    Focus on Lipids Care...
    February 19, 2019

    Icosapent ethyl reduces ischemic events in patients with hypertriglyceridemia

    READ
  • Endocrine/Rheum
    Rheumatology...
    February 19, 2019

    Glucosamine may be an option for knee osteoarthritis

    READ
  • Endocrine/Rheum
    Endocrinology...
    February 11, 2019

    Cardiovascular risks of fertility treatments

    READ
  • Heart/Lungs
    Focus on Anticoagulat...
    February 11, 2019

    New data support apixaban over rivaroxaban for newly diagnosed...

    READ
  • ID/Cancers
    Oncology...
    February 5, 2019

    Treatment outcomes improved in nonmetastatic pancreatic cancer

    READ
  • Neuro/Psych
    Neurology...
    February 5, 2019

    Antiepileptic drugs associated with serious skin reactions

    READ
  • Neuro/Psych
    Psychiatry...
    January 28, 2019

    Off-label use of antipsychotics should be done cautiously in...

    READ
  • Personalized Care
    Drug Interactio...
    January 28, 2019

    Ketogenic diet affects valproic acid, phenobarbital serum...

    READ
  • Heart/Lungs
    Focus on Anticoagulat...
    January 22, 2019

    ASH releases new VTE guidelines

    READ
  • Endocrine/Rheum
    Focus on Diabetes...
    January 22, 2019

    Self-monitoring of blood glucose is not appropriate for everyone

    READ
  • ID/Cancers
    Focus on Immunizations...
    January 15, 2019

    Tdap immunization during third trimester passes on protection to...

    READ
  • Read more about FDA approves new drug to treat travelers’ diarrhea
  • Read more about FDA approves expanded use for first-line treatment of peripheral T-cell lymphoma
  • Read more about Drug now approved to treat HCC, most common type of liver cancer
  • Read more about FDA approves new version of Primatene Mist for mild asthma
  • Read more about New sublingual opioid approved for use in health care settings only
  • Read more about FDA approves pegfilgrastim biosimilar
  • Read more about Combined with standard immunosuppressive therapy, drug targets treatment-resistant SAA
  • Read more about New oncology drug targets specific genetic biomarker instead of tumor type
  • Read more about Medications used for substance abuse disorders may reduce suicidality, crime
  • Read more about Factors that may predict sustained efficacy after a short course of OTC PPIs

Medication Monitor

NEW DRUG APPROVALS

  • February 7, 2019
    Caplacizumab-yhdp
    (Cablivi):
    FDA approves first drug therapy for adults with rare blood clotting disorder
  • February 6, 2019
    PrabotulinumtoxinA-xvfs
    (Jeuveau):
    New product approved for 'frown lines'
See more New Drug Approvals

SUPPLEMENTAL APPROVALS

  • February 22, 2019
    Pembrolizumab
    (Keytruda):
    FDA approves pembrolizumab for adjuvant treatment of melanoma
  • February 6, 2019
    Cabozantinib
    (Cabometyx):
    FDA approves cabozantinib tablets for previously treated hepatocellular carcinoma
See more Supplemental Approvals

ALERTS AND RECALLS

  • February 22, 2019
    Febuxostat
    (Uloric):
    FDA adds boxed warning for increased risk of death with gout medication
See more Alerts and Recalls

PRODUCT WITHDRAWALS

  • March 26, 2018
    Daclizumab
    (Zinbryta):
    Daclizumab withdrawn after reports of serious inflammatory brain disorders
See more Product withdrawals


                                

Editor's Picks

  • Icosapent ethyl reduces ischemic events in...
  • Glucosamine may be an option for knee...
  • Cardiovascular risks of fertility treatments
  • New data support apixaban over rivaroxaban for...
  • Treatment outcomes improved in nonmetastatic...

Popular Articles

  • Common antibiotics do not appear to interact with...
  • New oral option for cancer-associated VTE
  • Updated Clostridium difficile guidelines released
  • Pharmacist interventions at black barbershops...
  • New analysis compares efficacy and safety of...

Popular Sections

  • Alerts and Recalls
  • Supplemental Approvals
  • New Drug Approvals
  • Cardiology
  • Alternative Medicines Corner

2215 Constitution Avenue NW, Washington, DC 20037 Telephone 202-628-4410 Fax 202-783-2351

© 2013 American Pharmacists Association All Rights Reserved.

About the American
Pharmacists Association

The American Pharmacists Association (APhA) is the organization whose members are recognized in society as essential in all patient care settings for optimal medication use that improves health, wellness and quality of life. Through information, education and advocacy, APhA empowers its members to improve medication use and advance patient care.

More info

About APhA DrugInfoLine

APhA DrugInfoLine (ISSN 2162-3015) is a weekly publication of, and is owned and copyrighted by the American Pharmacists Association, the national professional society of pharmacists. Materials in APhA DrugInfoLine do not neccessarily represent the policy, recommendations, or endorsement of APhA. The publisher, authors, editors, reviewers, and contributors have taken care to ensure that the information contained in APhA DrugInfoLine is accurate and current; however, they shall have no ability to any person or entity with regard to claims, losses, or damage caused or alleged to be caused, directly or indirectly by use of any information contained in the publication. All decisions about drug therapy must be based on independent judgement of the clinician.

  • Contact Us
  • Section Advisors
  • Terms of Use
  • Privacy Policy